Status:
NOT_YET_RECRUITING
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
Lead Sponsor:
University of California, Davis
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Doris Duke Charitable Foundation
Conditions:
Sickle Cell Disease
Sickle Cell Anemia
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
Detailed Description
The investigators hypothesize that adults with sickle cell disease (SCD) and osteonecrosis of the femoral (hip) and/or humeral (shoulder) heads will tolerate oral alendronate 70 mg administered once a...
Eligibility Criteria
Inclusion
- Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
- Ability to provide written informed consent
- Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
- Negative urine pregnancy test for anyone of childbearing potential at study entry
Exclusion
- Pregnant women
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Prisoners
- Hospitalizations (for any cause) within 2 weeks of study entry
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06016634
Start Date
December 1 2025
End Date
December 31 2027
Last Update
December 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UC Davis Comprehensive Cancer Center
Sacramento, California, United States, 95817